The problem of cardiac safety of nonsteroidal anti-inflammatory drugs

Abstract


The paper considers an update on the mechanisms for the development of adverse reactions of nonsteroidal anti-inflammatory drugs on the cardiovascular system.

References

  1. Intercontinental Marketing Services (IMS) Health, II Mercato Farmaceutico 2001-2002.
  2. Singh G, Miller JD, Huse DM, Pettitt D, D’Agostino RB, Russell MW. Consequences of increased systolic blood pressure in patients with osteoarthrosis and rheumatoid arthritis. J Rheumat. 2003;30(4):714-719.
  3. Verdecchia P, Angeli F, Mazzotta G, Gentile G, Reboldi G. Emerging therapeutic strategies on osteoarthritis patients with hypertension. EULAR Sattellite symposium: Optimising the management of osteoarthritis: emerging therapies. Br Med J. 2010;27.
  4. Wolfe F, Zhao S, Pettitt D. Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. J Rheumatol. 2004;31(6):1143-1151.
  5. Harris RC, Breyer MD. Update on Cyclooxygenase-2 Inhibitors. Clin J Am Soc Nephrol. 2006;1(2):236-245.
  6. Cheng HF, Harris RC. Cyclooxygenases, the kidney, and hypertension. Hypertension. 2004;43(3):525-530. doi: 10.1161/01.HYP.0000116221.27079.ea
  7. Chan CC, Reid CM, Aw TJ, Liew D, Haas SJ, Krum H. Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis. J Hypertens. 2009;27(12):2332-2341. doi: 10.1097/HJH.0b013e3283310dc9.
  8. Johnson AG, Nguyen TV, Day RО. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 1994;121(4):289-300.
  9. Клинические рекомендации. Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике Современная ревматология. 2015;(1):4-23.
  10. Harirforoosh S, Asghar W, Jamali F. Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. J Pharm Pharm Sci. 2013;16(5):821-847.
  11. Bombardier C, Lane L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ; VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. New Engl J Med. 2000;343(21):1520-1528.
  12. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA; Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in colorectal adenomatous chemoprevention trail. N Engl J Med. 2005;352(11):1092-1102.
  13. Schaeverbeke T, Heloire F, Deray G. How to watch over a patient treated with a NSAID in relation to the cardiovascular and renal risk? Presse Med. 2006;35(99)Suppl 1:41-46.
  14. Jamali F. Arthritis is associated with cardiovascular disease in the users of analgesics and nonsteroidal anti-inflammatory drugs. Arch Intern Med. 2007;167(21):2371-2372.
  15. Попкова Т.В., Новикова Д.С., Новиков А.А., Александрова Е.Н., Герасимова Е.В., Мач Э.С., Насонов Е.Л. Роль системного воспаления в развитии сердечно-сосудистых осложнений при ревматоидном артрите. Научно-практическая ревматология. 2009;3(прил.):61-70.
  16. Singh G, Miller JD, Huse DM, Pettitt D, D’Agostino RB, Russell MW. Consequences of increased systolic blood pressure in patients with osteoarthrosis and rheumatoid arthritis. J Rheumat. 2003;30(4):714-719.
  17. Warksman JC, Brody A, Phillips SD. Nonselecive nonsteroidal anti-inflammatory drugs and cardiovascular risk: are they safe? Ann Pharmacother. 2007;41(7):1163-1173.
  18. Caldwell B, Aldington S, Weatherall M, Shirtcliffe P, Beasley R. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med. 2006;99(3):132-140.
  19. Juni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004;364(9450):2021-2029.
  20. Инструкция по медицинскому применению препарата Мовалис, суспензия для приема внутрь. РУ: ЛС-001185. http://www.grls.rosminzdrav.ru/Grls_View. aspx?idReg=26226&t=f00ff c17-05a2-4610938c-b2b1236d641b
  21. Asghar W, Jamali F. The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review. Inflammopharmacology. 2015;23(1):1-16. doi: 10.1007/s10787-014-0225-9.
  22. Ungprasert P, Matteson EL, Thongprayoon C. Nonaspirin Nonsteroidal Anti-Inflammatory Drugs and Risk of Hemorrhagic Stroke: A Systematic Review and Meta-Analysis of Observational Studies. Stroke. 2016;47:356-364. doi: 10.1161/STROKEAHA.115.011678.
  23. Moodley I. Review of the cardiovascular safety of COXIBs compared to NSAIDS. Cardiovasc J Afr. 2008;19(2):102-107.
  24. Garcia Rodriguez LA, Hernandez-Diaz S. Nonsteroidal anti-inflammatory drugs as a trigger of clinical heart failure. Epidemiology. 2003;14(2):240-246.
  25. Цветкова Е.С. Мелоксикам: применение внутримышечной формы в ревматологии. Терапевтический архив. 2003;75(8):96-97.
  26. Alvarez-Nemegyei J, Rubio-Solís EN, Herrera-Correa GM. Effect of short-term nonsteroidal antiinflammatory therapy on mean blood pressure. A prospective, randomized clinical trial. Reumatol Clin. 2006;2(1):10-14. doi: 10.1016/S1699-258X(06)73014-5.
  27. Повереннова И.Е., Золотовская И.А. Цереброваскулярные риски и прогнозирование развития осложнений у пациентов с болью в спине на фоне приема нестероидных противовоспалительных препаратов. Терапевтический архив. 2015;87(5): 53-57.
  28. Varas-Lorenzo C, Riera-Guardia N, Calingaert B, Castellsague J, Salvo F, Nicotra F, Sturkenboom M, Perez-Gutthann S. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiol Drug Saf. 2013;22(6):559-570.
  29. Gislason GH, Jacobsen S, Rasmussen JN, Rasmussen S, Buch P, Friberg J, Schramm TK, Abildstrom SZ, Køber L, Madsen M, Torp-Pedersen C. Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation. 2006;113(25):2906-2013.
  30. McAdam BF, Catella Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX) 2: the human pharmacology of a selective inhibitors of COX 2. Proc Natl Acad Sci USA. 19995;96(1):272-277.
  31. Clark DW, Layton D, Shakir SA. Do some inhibitors of COX-2 increase of tromboembolic events? Linking pharmacology with pharmacoepidemiology. Drug Saf. 2004;27(7):427-456.
  32. Мазуров В.И., Якушева В.А., Беляева И.Б. Применение мелоксикама (мовалиса у больных с ревматическими заболеваниями с сопутствующей ишемической болезнью сердца. Клиническая медицина. 2004;82(12):54-59.
  33. Беляева И.Б. Эффективность мелоксикама (мовалиса) при ревматических заболеваниях. Фарматека. 2008;(5):19-25.
  34. Freestone S, Bello A. Comparison of the effect of celecoxib, meloxicam, and nimesulide on platelet function in healthy subjects. Ann Rheum Dis. 2005;64(Suppl III):495.
  35. Knijff-Dutmer EA, Kalsbeek-Batenburg EM, Koerts J, van de Laar MA. Platelet function is inhibited by non-selective non-steroidal antiinflammatory drugs but not by cyclo-oxygenase-2-selective inhibitors in patients with rheumatoid arthritis. Rheumatology (Oxford). 2002;41(4):458-461.
  36. Van Ryn J, Kink-Eiband M, Kuritsch I, Feifel U, Hanft G, Wallenstein G, Trummlitz G, Pairet M. Meloxicam does not affect the antiplatelet effect of aspirin in healthy male and female volunteers. J Clin Pharmacol. 2004;44(7):777-784.
  37. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, Vyas SN, FitzGerald GA. Cyclooxygenase inhibitors and the antiplatelet effect of aspirin. N Engl J Med. 2001;345(25):1809-1817.
  38. Capone ML, Sciulli MG, Tacconelli S, Grana M, Ricciotti E, Renda G, Di Gregorio P, Merciaro G, Patrignani P. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol. 2005;45(8):1295-1301.
  39. Mueller FO, Middle MV, Schall R, Terblanché J, Hundt HK, Groenewoud G. An evaluation of the interaction of meloxicam with frusemide in patients with compensated chronic cardiac failure. Br J Clin Pharmacol. 1997;44(4):393-398.
  40. Tuerck D, Su CAPF, Heinzel G, Busch U, Bluhmki E, Hoffmann J. Lack of interaction between meloxicam and warfarin in healthy volunteers. Eur J Clin Pharmacol. 1997;51(5):421-425.
  41. Altman R, Luciardi HL, Muntaner J, Del Rio F, Berman SG, Lopez R, Gonzalez C. Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) pilot study. Circulation. 2002;106(2):191-195.

Statistics

Views

Abstract - 82

PDF (Russian) - 16

Cited-By


Article Metrics

Metrics Loading ...

Refbacks

  • There are currently no refbacks.

Copyright (c) 2020 Shostak N.A., Klimenko A.A., Demidova N.A., Kondrashov A.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies